{"id":2773,"date":"2020-06-01T17:58:42","date_gmt":"2020-06-01T17:58:42","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&#038;p=2773"},"modified":"2020-07-08T07:45:47","modified_gmt":"2020-07-08T07:45:47","slug":"genetic-risk-assessment-in-heart-failure-impact-of-genetic-variation-of-beta-1-adrenergic-receptor-gly389arg-polymorphism","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/genetic-risk-assessment-in-heart-failure-impact-of-genetic-variation-of-beta-1-adrenergic-receptor-gly389arg-polymorphism\/","title":{"rendered":"Genetic Risk Assessment In Heart Failure: Impact Of Genetic Variation Of Beta 1 Adrenergic Receptor GLY389ARG Polymorphism"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0.9);background-position: center center;background-repeat: no-repeat;padding-top:20px;padding-right:20px;padding-bottom:20px;padding-left:20px;margin-bottom: 0px;margin-top: 0px;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:20px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-1\"><h2 id=\"title\" class=\"scroll-target style-scope patent-result\">Genetic Risk Assessment In Heart Failure: Impact Of Genetic Variation Of Beta 1 Adrenergic Receptor GLY389ARG Polymorphism<\/h2>\n<\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third fusion-column-first\" style=\"width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% ) * 0.66666666666667 ) );margin-right: 4%;margin-top:0px;margin-bottom:20px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-2\"><p><strong>Inventors:<\/strong> Dennis Michael McNamara: Manuel Worcel: Michael L. Sabolinski: Sang William Tam<\/p>\n<p><strong>Patent Number:<\/strong> 12\/088,923<\/p>\n<div class=\"horizontal layout style-scope patent-result\">\n<div class=\"flex-3 style-scope patent-result\">\n<section id=\"abstract\" class=\"style-scope patent-result\">\n<h3 class=\"flex style-scope patent-result\">Abstract<\/h3>\n<div class=\"layout horizontal style-scope patent-text\">\n<section id=\"text\" class=\"flex style-scope patent-text\">\n<div id=\"p-0001\" class=\"abstract style-scope patent-text\">The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and\/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and\/or isosorbide mononitrate.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:30px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-0 fusion_builder_column_inner_1_2 1_2 fusion-one-half fusion-column-first\" style=\"width:50%;width:calc(50% - ( ( 4% ) * 0.5 ) );margin-right: 4%;margin-top:0px;margin-bottom:20px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-align-block\"><style>.fusion-body .fusion-button.button-1{border-radius:0px 0px 0px 0px;}<\/style><a class=\"fusion-button button-flat fusion-button-default-size button-default button-1 fusion-button-default-span fusion-button-default-type\" target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/patents.google.com\/patent\/US20090192128A1\/en?oq=12%2f088%2c923\" style=\"width:calc(100%);\"><span class=\"fusion-button-text\">View Google Patent Page<\/span><\/a><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-1 fusion_builder_column_inner_1_2 1_2 fusion-one-half fusion-column-last\" style=\"width:50%;width:calc(50% - ( ( 4% ) * 0.5 ) );margin-top:0px;margin-bottom:20px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-align-block\"><style>.fusion-body .fusion-button.button-2{border-radius:0px 0px 0px 0px;}<\/style><a class=\"fusion-button button-flat fusion-button-default-size button-default button-2 fusion-button-default-span fusion-button-default-type\" target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/mirm-pitt.net\/technologies\/wp-content\/uploads\/2020\/06\/US20090192128A1.pdf\" style=\"width:calc(100%);\"><span class=\"fusion-button-text\">Download PDF<\/span><\/a><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_3 1_3 fusion-one-third fusion-column-last\" style=\"width:33.333333333333%;width:calc(33.333333333333% - ( ( 4% ) * 0.33333333333333 ) );margin-top:0px;margin-bottom:20px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-3\"><h3 id=\"title\" class=\"scroll-target style-scope patent-result\"><\/h3>\n<\/div><style type=\"text\/css\">.fusion-gallery-1 .fusion-gallery-image {border:0px solid #f6f6f6;}<\/style><div class=\"awb-gallery-wrapper awb-gallery-wrapper-1 button-span-no\"><div class=\"fusion-gallery fusion-gallery-container fusion-grid-2 fusion-columns-total-0 fusion-gallery-layout-grid fusion-gallery-1\" style=\"margin:-2px;\"><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","format":"standard","meta":[],"portfolio_category":[11,125,132,20,16,17],"portfolio_skills":[],"portfolio_tags":[],"_links":{"self":[{"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/avada_portfolio\/2773"}],"collection":[{"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/avada_portfolio"}],"about":[{"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/types\/avada_portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/comments?post=2773"}],"version-history":[{"count":1,"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/avada_portfolio\/2773\/revisions"}],"predecessor-version":[{"id":2787,"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/avada_portfolio\/2773\/revisions\/2787"}],"wp:attachment":[{"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/media?parent=2773"}],"wp:term":[{"taxonomy":"portfolio_category","embeddable":true,"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/portfolio_category?post=2773"},{"taxonomy":"portfolio_skills","embeddable":true,"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/portfolio_skills?post=2773"},{"taxonomy":"portfolio_tags","embeddable":true,"href":"https:\/\/mirm-pitt.net\/technologies\/wp-json\/wp\/v2\/portfolio_tags?post=2773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}